GlassScriptPhysician profile
Keri Munyan
NPI 1568962116
$2,200.91
in general payments reported to CMS, 2019-2025
22 companies · $84.28 in 2025
The $84.28 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $920 · 2022: $890 · 2023: $292 · 2024: $15.45 · 2025: $84.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $742.29 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $283.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $213.72 | 2021-2022 | |
| Lilly USA, LLC | $194.28 | 2021-2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $174.28 | 2022 | |
| Daiichi Sankyo INC. | $124.72 | 2021 | |
| Novo Nordisk INC | $79.13 | 2021-2022 | |
| Medtronic, INC. | $67.63 | 2023 | Signia |
| Otsuka America Pharmaceutical, INC. | $47.34 | 2021-2022 | |
| Eisai INC. | $36.28 | 2021 | |
| Boston Scientific Corporation | $31.49 | 2025 | General - Therapies |
| Amgen INC. | $30.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.41 | 2021 | |
| Nevro Corp. | $20.50 | 2022 | |
| Cranial Technologies, INC | $18.36 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $18.27 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.15 | 2022 | |
| Antares Pharma, INC. | $16.85 | 2022 | |
| Merck Sharp & Dohme LLC | $16.39 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $15.85 | 2022 | |
| Glaxosmithkline, LLC. | $12.17 | 2021 | |
| Pfizer INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Munyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.